Stockscreener 앱 받기
3.1201
31.39%
-1.4199
전일 마감가:
$4.54
열려 있는:
$3.6
하루 거래량:
219.86K
Relative Volume:
3.88
시가총액:
$35.76M
수익:
$10.96M
순이익/손실:
$-7.02M
주가수익비율:
-4.8752
EPS:
-0.64
순현금흐름:
$-3.72M
1주 성능:
+61.40%
1개월 성능:
+46.93%
6개월 성능:
-30.47%
1년 성능:
-43.36%
1일 변동 폭
$3.00
$3.855
1주일 범위
$1.93
$4.98
52주 변동 폭
$1.55
$5.61
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
CLGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
3.12 | 23.02M | 10.96M | -7.02M | -3.72M | -0.64 |
|
ONC
Beone Medicines Ltd Adr
|
243.65 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.77 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
79.86 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.05 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-17 | 개시 | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd 주식(CLGN)의 최신 뉴스
CollPlant (CLGN) Announces $3.6M Direct Offering and Private Placement - GuruFocus
CollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offering - MSN
CollPlant (CLGN) Announces New Share and Warrant Sale Agreement - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRE - GuruFocus
CollPlant announces $3.6 million stock offering By Investing.com - Investing.com India
CollPlant announces $3.6 million stock offering - Investing.com Australia
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES - PR Newswire
CollPlant Biotechnologies (NASDAQ:CLGN) Price Target Lowered to $12.00 at D. Boral Capital - Defense World
CollPlant Biotechnologies Reports Strong Q1 2025 Results - TipRanks
Collplant Biotechnologies Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN S - GuruFocus
CollPlant Biotechnologies (CLGN) Analyst Ratings Update | CLGN Stock News - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL R - GuruFocus
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - Nasdaq
CollPlant Biotechnologies (CLGN) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Earnings Preview: CollPlant Biotechnologies - Nasdaq
Global Tissue Engineering Market Insights & Industry Outlook | - openPR.com
When Will CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Breakeven? - simplywall.st
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINAN - GuruFocus
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS - Financial Times
Renaissance Technologies LLC Acquires New Stake in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World
Here's Why We're A Bit Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation - Yahoo Finance
CLGNCollplant Biotechnologies Ltd Latest Stock News & Market Updates - Stock Titan
Collplant stock hits 52-week low at $2.14 amid market challenges - Investing.com India
Collplant stock hits 52-week low at $2.14 amid market challenges By Investing.com - Investing.com South Africa
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevan - GuruFocus
FDA Animal Testing Phase-Out: How CollPlant's BioInk Tech Could Revolutionize Drug Safety Studies - Stock Titan
Collplant stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Collplant stock hits 52-week low at $2.47 amid market challenges - Investing.com India
CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at D. Boral Capital - The AM Reporter
D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Collplant plans clinical trials for dermal filler and advances regenerative implants - MSN
CollPlant Biotechnologies (CLGN) to Release Earnings on Thursday - Defense World
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2024 Earnings Call Transcript - Insider Monkey
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highl - GuruFocus
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ... By GuruFocus - Investing.com Canada
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Decline in Short Interest - Defense World
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - StreetInsider.com
Earnings call transcript: Collplant Biotechnologies Q4 2024 misses forecasts - Investing.com India
CollPlant Biotechnologies Reports 2024 Financial Results - TipRanks
CollPlant’s Earnings Call: Mixed Outlook Amid Innovations - TipRanks
SEC Form 20-F filed by CollPlant Biotechnologies Ltd - Quantisnow
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Collplant stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Collplant stock hits 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
What To Expect From CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings - GuruFocus
Collplant Biotechnologies Ltd expected to post a loss of 28 cents a shareEarnings Preview - TradingView
CollPlant Biotechnologies (CLGN) to Release Quarterly Earnings on Wednesday - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - Quantisnow
Collplant Biotechnologies Ltd (CLGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.38%
1.10%
자본화:
|
볼륨(24시간):